Publications

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

Silk SE. et al, (2023), Med (New York, N.Y.)

Systematic review of the diagnosis and management of necrotising otitis externa: Highlighting the need for high-quality research.

Takata J. et al, (2023), Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 48, 381 - 394

UK consensus definitions for necrotising otitis externa: a Delphi study.

Hodgson SH. et al, (2023), BMJ Open, 13

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.

Odera DO. et al, (2023), Science translational medicine, 15

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Hodgson SH. et al, (2022), Clinical and translational science, 15, 524 - 534

Characteristics, management and outcome of large Necrotising Otitis Externa case series: Need for Standardised Case Definition.

Hodgson SH. et al, (2022), The Journal of laryngology and otology, 1 - 32

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.

Kimingi HW. et al, (2022), Frontiers in immunology, 13

Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders

Chi PC. et al, (2021), Trials, 22

Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal Testing

Vanderslott S. et al, (2021), Science, Technology, & Human Values, 016224392110570 - 016224392110570

Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom

Vanderslott S. et al, (2021), BMJ Global Health, 6, e006305 - e006305

Clinical validation of optimised RT-LAMP for the diagnosis of SARS-CoV-2 infection.

Lim B. et al, (2021), Scientific reports, 11

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Development and internal validation of clinical prediction models for outcomes of complicated intra-abdominal infection.

Ahmed S. et al, (2021), The British journal of surgery, 108, 441 - 447

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.

Hodgson SH. et al, (2021), The Lancet. Infectious diseases, 21, e26 - e35

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Cookies on this website

Publications